Abstract: An oral sustained release pharmaceutical composition comprising a plurality of granules having diameters of not more than 1000 ?m, wherein each of the granules comprise a nucleus granule comprised of beraprost sodium and a coating agent coating the nucleus granule, and wherein the coating agent is comprised of a first skin layer containing one or more relatively water-insoluble macromolecular substances, and a second skin layer containing one or more hot-melt low-melting substances.

Abstract: Granules and coated granules, characterized in that they contain the following: a core containing at least one active ingredient which is optionally associated with at least one waxlike compound and optionally at least one polymer and/or binding agent; at least three successive layers of coating from the core outwards; a functional polymer coating (1) optionally containing a waxlike compound, enabling immediate, delayed or prolonged release, which can have a structure which is different from that of the first but which has a complimentary release function and which conditions the suspension medium.

Abstract: An oral sustained release pharmaceutical composition comprising a plurality of granules having diameters of not more than 1000 ?m, wherein each of the granules comprise a nucleus granule comprised of beraprost sodium and a coating agent coating the nucleus granule, and wherein the coating agent is comprised of a first skin layer containing one or more relatively water-insoluble macromolecular substances, and a second skin layer containing one or more hot-melt low-melting substances.

Abstract: Granules and coated granules, characterized in that they contain the following: a core containing at least one active ingredient which is optionally associated with at least one waxlike compound and optionally at least one polymer and/or binding agent; at least three successive layers of coating from the core outwards; a functional polymer coating (1) optionally containing a waxlike compound, enabling immediate, delayed or prolonged release, which can have a structure which is different from that of the first but which has a complimentary release function and which conditions the suspension medium.

Abstract: A dry, reconstitutable telitiromycin suspension characterized in that it contains granules or granules comprising a core containing telithromycin which is optionally associated with at least one waxlike compound and optionally with at least one polymer and/or binding agent, and at least three successive layers of coating from the core outwards, said granules being associated with excipients including at least one thickening agent, at least one preservative agent and at least one pH modulator agent.